Herbs in Epilepsy: Evidence for Efficacy, Toxicity, and Interactions

Seminars in Pediatric Neurology

Volumn 18, Issue 3, 2011, Pages 203-208

  Pearl, Phillip L ^a   Drillings, Ian M ^a   Conry, Joan A ^a  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AIGIN; ANTARES; ANTICONVULSIVE AGENT; ARDEYDYSTIN; BLUE COHOSH LOW ALCOHOL; BLUE COHOSH ROOT; CARBAMAZEPINE; CRYPTENAMINE; FRESH UPPER LEAVES; HERB A CALM FORMULA; HERBACEOUS AGENT; HERBAGESSIC FORMULA; HERBVAL FORMULA; KAVA; KAVA EXTRACT; KAVA KAVA LIQUID; KAVATROL; MELATONIN; NERVONOCTON N; PHYTO SURGE; PLACEBO; UNCLASSIFIED DRUG; VALERAMIDE; VALERIAN; VALPROIC ACID; VISCUM ALBUM EXTRACT;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ANAPHYLAXIS; ANOREXIA; ANXIETY DISORDER; ARTEMISIA VULGARIS; ARTERIOSCLEROSIS; ASTHMA; ATAXIA; AUTONOMIC NEUROPATHY; BRADYCARDIA; BRONCHITIS; CENTRAL NERVOUS SYSTEM DISEASE; CHIMAPHILA UMBELLATE; COMA; COMPLEX PARTIAL SEIZURE; CONFUSION; CONTACT DERMATITIS; DEPRESSION; DIARRHEA; DIZZINESS; DROWSINESS; DRUG ANTAGONISM; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG METABOLISM; DYSPNEA; EPILEPSY; FASCICULATION; GASTRITIS; GASTROINTESTINAL DISEASE; GASTROINTESTINAL IRRITATION; HEADACHE; HEART ARREST; HEART ARRHYTHMIA; HEART PALPITATION; HEARTBURN; HEMATURIA; HEPATITIS; HERB DRUG INTERACTION; HERBAL MEDICINE; HUMAN; HYPERSALIVATION; HYPERTENSION; HYPOREFLEXIA; HYPOTENSION; INFERTILITY; INSOMNIA; INTRACTABLE EPILEPSY; JET LAG; KIDNEY DISEASE; LIVER DYSFUNCTION; LIVER TOXICITY; LUNG DISEASE; LYMPHOCYTOPENIA; MEDICINAL PLANT; MICTURITION DISORDER; MIOSIS; MUSCLE HYPERTONIA; MUSCLE SPASM; MYDRIASIS; NAUSEA; NEMATODIASIS; NEOPLASM; NEURALGIA; ODOR; OPHTHALMOPLEGIA; PAIN; PARESTHESIA; PERITONITIS; PNEUMONIA; PSYCHOSIS; RECOMMENDED DRUG DOSE; RESPIRATION DEPRESSION; RESPIRATORY TRACT DISEASE; REVIEW; RHEUMATIC DISEASE; SCUTELLARIA; SCUTELLARIA BAICALENSIS; SCUTELLARIA LATERIFOLIA; SEDATION; SEIZURE; SEXUALLY TRANSMITTED DISEASE; SIDE EFFECT; SKIN ALLERGY; SLEEP DISORDER; STACHYS; STACHYS OFFICINALIS; STOMACH PAIN; STUPOR; SYNCOPE; TACHYCARDIA; TASTE; THROMBOCYTOPENIA; TONIC CLONIC SEIZURE; TOOTH PAIN; ULCER; UTERUS CONTRACTILITY; UTERUS CONTRACTION; VALERIANA OFFICINALIS; VERATRUM; VERATRUM VIRIDE; VISION; VOMITING; WEAKNESS; WEIGHT REDUCTION; WOUND;

ANTICONVULSANTS; EPILEPSY; HUMANS; PHYTOTHERAPY; PLANTS, MEDICINAL;

EID: 80655144956     PISSN: 10719091     EISSN: 15580776     Source Type: Journal    
DOI: 10.1016/j.spen.2011.06.007     Document Type: Review

References (49)

1. Astin J.A. Why patients use alternative medicine: Results of a national study. JAMA 1998, 279:1548-1553.
2. Tindle H.A., Davis R.B., Phillips R.S., et al. Trends in use of complementary and alternative medicine by US adults: 1997-2002. Altern Ther Health Med 2005, 11:42-49.
3. Wells R.E., Phillips R.S., Schachter S.C., et al. Complementary and alternative medicine use among US adults with common neurological conditions. J Neurol 2010, 257:1822-1831.
4. Blumenthal M., Brinkmann J. Herbal Medicine: Expanded Commission E Monographs. Newton, NJ, Integrative Medicine Communications 2000.
5. Fetrow C.W., Avila J.R. Professional's Handbook of Complementary and Alternative Medicines (ed 2) 2001, Springhouse Corporation, Springhouse, PA.
6. Grunze H., Langosch J., Schirrmacher K., et al. Kava pyrones exert effects on neuronal transmission and transmembraneous cation currents similar to established mood stabilizers-A review. Prog Neuropsychopharmacol Biol Psychiatry 2001, 25:1555-1570.
7. Pittler M.H., Ernst E. Efficacy of kava extract for treating anxiety: Systematic review and meta-analysis. J Clin Psychopharmacol 2000, 20:84-89.
8. Volz H.P., Kieser M. Kava-kava extract WS 1490 versus placebo in anxiety disorders-A randomized placebo-controlled 25-week outpatient trial. Pharmacopsychiatry 1997, 30:1-5.
9. Connor K.M., Davidson J.R., Churchill L.E. Adverse-effect profile of kava. CNS Spectr 2001, 6:848-853.
10. Amabeoku G.J., Leng M.J., Syce J.A. Antimicrobial and anticonvulsant activities of Viscum capense. J Ethnopharmacol 1998, 61:237-241.
11. Horneber M.A., Bueschel G., Huber R., et al. Mistletoe therapy in oncology. Cochrane Database Syst Rev 2008, 2:CD003297.
12. Cardini F., Weixin H. Moxibustion for correction of breech presentation: A randomized controlled trial. JAMA 1998, 280:1580-1584.
13. Smolianinov E.S., Goldberg V.E., Matiash M.G., et al. Effect of Scutellaria baicalensis extract on the immunologic status of patients with lung cancer receiving antineoplastic chemotherapy. Eksp Klin Farmakol 1997, 60:49-51.
14. Goldberg V.E., Ryzhakov V.M., Matiash M.G., et al. Dry extract of Scutellaria baicalensis as a hemostimulant in antineoplastic chemotherapy in patents with lung cancer. Eksp Klin Farmakol 1997, 60:28-30.
15. Chung C.P., Park J.B., Bae K.H. Pharmacological effects of methanolic extract from the root of Scutellaria baicalensis and its flavonoids on human gingival fibroblast. Planta Med 1995, 61:150-153.
16. Razina T.G., Udintsev S.N., Prishchep T.P., et al. Enhancement of the selectivity of the action of the cytostatics cyclophosphane and 5-fluorouracil by using an extract of the Baikal skullcap in an experiment. Vopr Onkol 1987, 33:80-84.
17. Shao Z.H., Li C.Q., Vanden Hoek T.L., et al. Extract from Scutellaria baicalensis Georgi attenuates oxidant stress in cardiomyocytes. J Mol Cell Cardiol 1999, 31:1885-1895.
18. Eadie M.J. Could valerian have been the first anticonvulsant?. Epilepsia 2004, 45:1338-1343.
19. Bialer M., Johannessen S.I., Kupferberg H.J., et al. Progress report on new antiepileptic drugs: A summary of the Fifth Eilat Conference (Eilat V). Epilepsy Res 2001, 43:11-58.
20. Spinella M. Herbal Medicines and epilepsy: The potential for benefit and adverse effects. Epilepsy Behav 2001, 2:524-532.
21. Fariello R.G., Bubenik G.A., Brown G.M., et al. Epileptogenic action of intraventricularly injected antimelatonin antibody. Neurology 1977, 27:567-570.
22. Philo R., Reiter R.J. Characterization of pinealectomy induced convulsions in the Mongolian gerbil (Meriones unguiculatus). Epilepsia 1978, 19:485-492.
23. Azevedo B.A., Fontana P. Audiogenic seizures and the pineal gland. Biol Psychiatry 1988, 23:734-740.
24. Rao M.L., Stefan H., Bauer J. Epileptic but not psychogenic seizures are accompanied by simultaneous elevation of serum pituitary hormones and cortisol levels. Neuroendocrinology 1989, 49:33-39.
25. Miyamoto A., Oki J., Takahashi S., et al. Serum melatonin kinetics and long-term melatonin treatment for sleep disorders in Rett syndrome. Brain Dev 1999, 21:59-62.
26. Sheldon S.H. Pro-convulsant effects of oral melatonin in neurologically disabled children. Lancet 1998, 351:1254.
27. Fauteck J., Schmidt H., Lerchl A., et al. Melatonin in epilepsy: First results of replacement therapy and first clinical results. Biol Signals Recept 1999, 8:105-110.
28. Elkhayat H.A., Hassanein S.M., Tomoum H.Y., et al. Melatonin and sleep-related problems in children with intractable epilepsy. Pediatr Neurol 2010, 42:249-254.
29. Monteleone P., Tortorella A., Borriello R., et al. Suppression of nocturnal plasma melatonin levels by evening administration of sodium valproate in healthy humans. Biol Psychiatry 1997, 41:336-341.
30. Schapel G.J., Beran R.G., Kennaway D.L., et al. Melatonin response in active epilepsy. Epilepsia 1995, 36:75-78.
31. Weaver D.R. Reproductive safety of melatonin: A "wonder drug" to wonder about. J Biol Rhythms 1997, 12:682-689.
32. Buscemi N., Vandermeer B., Hooton N., et al. Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: Meta-analysis. BMJ 2006, 332:385-393.
33. Meredith S., Jackson K., Dudenhoeffer G., et al. Long-term supplementation with melatonin delays reproductive senescence in rats, without an effect on number of primordial follicles. Exp Gerontol 2000, 35:343-352.
34. Arendt J. Safety of melatonin in long-term use. J Biol Rhythms 1997, 12:673-681.
35. Cot J.M. Herb-drug interactions: Focus on pharmokinetics. CNS Spectr 2001, 6. 827-632.
36. Almeida J.C., Grimsley E.W. Coma from the health food store: Interaction between kava and alprazolam. Ann Intern Med 1996, 125:940-941.
37. Sigler M., Strassburg H.M., Boenigk H.E. Effective and safe but forgotten: Methsuximide in intractable epilepsies in childhood. Seizure 2001, 10:120-124.
38. Bonilha L., Li L.M. Heavy coffee drinking and epilepsy. Seizure 2004, 13:284-285.
39. Kaufman K.R., Sachdeo R.C. Caffeinated beverages and decreased seizure control. Seizure 2003, 12:519-521.
40. Chrościńska-Krawczyk M., Ratnaraj N., Patsalos P.N., et al. Effect of caffeine on the anticonvulsant effects of oxcarbazepine, lamotrigine and tiagabine in a mouse model of generalized tonic-clonic seizures. Pharmacol Rep 2009, 61:819-826.
41. Gasior M., Borowicz K., Buszewicz G., et al. Anticonvulsant activity of phenobarbital and valproate against maximal electroshock in mice during chronic treatment with caffeine and caffeine discontinuation. Epilepsia 1996, 37:262-268.
42. Obach R.S. Inhibition of human cytochrome P450 enzymes by constituents of St. John's wort, an herbal preparation used in the treatment of depression. J Pharmacol Exp Ther 2000, 294:88-95.
43. Li Y., Wang E., Patten C.J., et al. Effects of flavonoids on cytochrome P450-dependent acetaminophen metabolism in rats and human liver microsomes. Drug Metab Dispos 1994, 22:566-571.
44. Foster B.C., Foster M.S., Vandenhoek S., et al. An in vitro evaluation of human cytochrome P450 3A4 and P-glycoprotein inhibition by garlic. J Pharm Pharm Sci 2001, 4:176-184.
45. Budzinski J.W., Foster B.C., Vandenhoek S., et al. An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. Phytomedicine 2000, 7:273-282.
46. Leonessa F., Kim J.H., Ghiorghis A., et al. C-7 analogues of progesterone as potent inhibitors of the P-glycoprotein efflux pump. J Med Chem 2002, 45:390-398.
47. Cox D.S., Scott K.R., Gao H., et al. Influence of multidrug resistance (MDR) proteins at the blood-brain barrier on the transport and brain distribution of enaminone anticonvulsants. J Pharmacol Sci 2001, 90:1540-1552.
48. Granger A.S. Ginkgo biloba precipitating epileptic seizures. Age Ageing 2001, 30:523-525.
49. Haller C.A., Benowitz N.L. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med 2000, 343:1833-1838.